瑞波西利联合来曲唑治疗激素受体阳性、人表皮生长因子受体2阴性局部晚期或转移性乳腺癌的疗效、安全性及预后预测:3b期RIBECCA研究最终结果
RIBECCA是一项多中心、开放标签、单臂3b期研究,评估瑞波西利联合来曲唑在激素受体阳性、人表皮生长因子受体2阴性局部晚期或转移性乳腺癌患者中的疗效与安全性。487例可评估疗效,24周临床获益率为60.8%,总缓解率为19.3%。一线绝经后患者中位无进展生存期为21.8个月,绝经前及经治患者为11.0个月。
要点
- 24周临床获益率60.8%,总缓解率19.3%。
- 一线绝经后患者中位无进展生存期21.8个月。
- 绝经前及经治患者中位无进展生存期11.0个月。
核心结论
- 在广泛的激素受体阳性、人表皮生长因子受体2阴性局部晚期或转移性乳腺癌患者人群中,瑞波西利联合来曲唑的疗效和安全性结果与关键试验中观察到的结果相似。
研究设计与样本
- 多中心、开放标签、单臂3b期研究,纳入激素受体阳性、人表皮生长因子受体2阴性局部晚期或转移性乳腺癌且不适合根治性治疗、ECOG体能状态评分≤2的患者,接受瑞波西利联合来曲唑治疗。
- 队列A为一线治疗的绝经后女性和男性;队列B为一线治疗的绝经前/围绝经期女性(B1)以及针对晚期疾病既往接受过治疗的患者(B2)。
- 487例患者可评估疗效,502例可评估安全性;主要终点为第24周临床获益率,次要终点包括总缓解率、无进展生存期、总生存期和安全性。
主要发现
- 第24周临床获益率为60.8%(95%CI 56.3-65.1),总缓解率为19.3%(95%CI 15.9-23.1)。
- 一线绝经后患者中位无进展生存期为21.8个月(95%CI 13.9-25.3),绝经前及经治患者为11.0个月(95%CI 8.2-16.4)。
- 中位总生存期未达到。
- 基线ECOG体能状态评分较高、组织学分级较高和孕激素受体阴性对无进展生存期显示不利影响。
- 最常见不良事件为中性粒细胞减少(50.0%)、恶心(42.0%)和乏力(39.2%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In MONALEESA-2, addition of ribociclib to letrozole resulted in significantly longer progression-free survival (PFS) in postmenopausal women with HR+HER2- advanced breast cancer (ABC). RIBociclib for the treatment of advanCed breast CAncer (RIBECCA) study investigated ribociclib plus letrozole in a patient population reflecting routine clinical practice. PATIENTS AND METHODS: In this multicenter, open-label, single-arm, phase 3b study, patients with HR+HER2- ABC not amenable to curative therapy and ECOG performance status ≤ 2 received ribociclib plus letrozole (cohort A: postmenopausal women and men in first-line; cohort B: pre-/perimenopausal women in first-line [B1], patients pretreated for advanced disease [B2]). The primary endpoint was clinical benefit rate (CBR) by week 24; secondary endpoints included overall response rate (ORR), PFS, overall survival (OS), and safety. Association of patient and tumor characteristics with PFS was analyzed by multivariable Cox regression analysis. RESULTS: Overall, 487 patients were evaluable for efficacy, 502 for safety. By week 24, CBR was 60.8 % (95 % CI, 56.3-65.1), ORR was 19.3 % (95 % CI, 15.9-23.1). Median PFS was 21.8 months (95 % CI, 13.9-25.3) in first-line postmenopausal patients and 11.0 months (95 % CI, 8.2-16.4) in premenopausal and pretreated patients. Median OS was not reached. Higher baseline ECOG performance status, higher histological grade, and negative progesterone receptor status showed an unfavorable effect on PFS. Most common adverse events were neutropenia (50.0 %), nausea (42.0 %), and fatigue (39.2 %). CONCLUSION: In this broad population of patients with HR+HER2- ABC, efficacy and safety results of ribociclib plus letrozole were similar to those observed in pivotal trials.
引用
- Fasching PA, Decker T, Hartkopf A, et al. Efficacy, safety, and prognosis prediction in patients treated with ribociclib in combination with letrozole: Final results of phase 3b RIBECCA study in hormone receptor positive, human epidermal growth factor receptor-2 negative, locally advanced or metastatic breast cancer. Eur J Cancer. 2023. PMID: 38154393. doi:10.1016/j.ejca.2023.113480
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。